Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $8.10 USD
Change Today +0.05 / 0.62%
Volume 7.1K
ZSAN On Other Exchanges
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

zosano pharma corp (ZSAN) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/27/15 - $12.40
52 Week Low
06/30/15 - $7.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ZOSANO PHARMA CORP (ZSAN)

Related News

No related news articles were found.

zosano pharma corp (ZSAN) Related Businessweek News

No Related Businessweek News Found

zosano pharma corp (ZSAN) Details

Zosano Pharma Corporation, a clinical stage specialty pharmaceutical company, develops a proprietary transdermal microneedle patch system to deliver drug formulations through the skin for the treatment of various indications. The company’s lead product candidates include Daily ZP-PTH, a synthetic form of parathyroid hormone for treating severe osteoporosis, which has completed a Phase II trial; ZP-Glucagon, a hormone that raises blood glucose levels, intended for the emergency rescue of patients suffering from life-threatening, severe hypoglycemia, which is in Phase II clinical trial; and ZP-Triptan, a class of serotonin receptor agonists known as triptans, used for the treatment of migraine, which is in Phase I and II clinical trials. It has strategic partnership and license agreement with Eli Lilly and Company to develop ZP-PTH microneedle patch products; and Novo Nordisk A/S to develop a microneedle patch product to administer semaglutide for the treatment of type 2 diabetes. The company was founded in 2006 and is headquartered in Fremont, California.

26 Employees
Last Reported Date: 03/26/15
Founded in 2006

zosano pharma corp (ZSAN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $412.0K
Chief Medical Officer
Total Annual Compensation: $398.0K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $329.8K
Compensation as of Fiscal Year 2014.

zosano pharma corp (ZSAN) Key Developments

Zosano Pharma Corporation Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2015

Zosano Pharma Corporation announced unaudited consolidated financial results for the second quarter and six months ended June 30, 2015. The company reported a net loss for the second quarter of 2015 of $7.6 million, or $0.63 per share on a basic and diluted basis, compared with a net loss of $3.9 million, or $0.76 per share on a basic and diluted basis, the second quarter of 2014. Total revenue was $0.1 million, compared with $0.5 million in the second quarter of 2014. The decrease was primarily due to a reduction in license fee revenue and related development support service revenue upon the completion of the feasibility study under Zosano's collaboration agreement with Novo Nordisk. Loss from operations was $6.688 million, compared with $3.382 million a year ago. For the six months, the company reported total revenue was $0.313 million, compared with $2.107 million a year ago. Loss from operations was $10.839 million, compared with $5.95 million a year ago. Net loss was $12.162 million, or $1.12 per share on a basic and diluted basis, compared with a net loss of $6.281 million, or $1.23 per share on a basic and diluted basis a year ago.

Zosano Pharma Corporation Announces Board Appointments

Zosano Pharma Corporation announced additions with the hiring of Donald Kellerman, Pharm.D. as Vice President, Clinical Development; David Zhang, Ph.D. as Executive Director, Biostatistics and Data Management; and Jacquie Mardell as Senior Director, Clinical Operations. Dr. Donald Kellerman most recently served as Senior Vice President of Clinical Development & Regulatory Affairs at Tonix Pharmaceuticals. Previously, Dr. Kellerman served as Senior Vice President of Clinical Development & Medical Affairs at MAP Pharmaceuticals Inc. (acquired by Allergan Inc.) for five years. Dr. David Zhang joins Zosano from Genentech, a member of the Roche Group. During his 13-year career at Genentech, Dr. Zhang worked in clinical development across all phases in multiple therapeutic areas and geographic regions. Jacquie Mardell joins Zosano after serving for more than a year as clinical operations consultant for Zosano.

Zosano Pharma Announces Discontinuation of Novo Nordisk GLP-1 Patch Collaboration

Zosano Pharma Corporation announced that Novo Nordisk has notified Zosano of its intention to discontinue the collaboration agreement related to development of a transdermal presentation of select NVO glucagon-like peptide-1 (GLP-1) analogues. Zosano has been notified that the decision relates to a strategic prioritization of NVO's research portfolio despite continued progress during the collaboration period. Upon the expected termination of the agreement, all technology rights licensed to Novo Nordisk related to the field of GLP-1 products will revert to Zosano. Zosano and NVO entered into a collaboration agreement in January 2014 to develop a new transdermal presentation of NVO proprietary human GLP-1 analogues, to be administered once weekly using Zosano's microneedle patch system for the treatment of type 2 diabetes.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZSAN:US $8.10 USD +0.05

ZSAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $144.21 USD +0.31
Corium International Inc $10.45 USD -0.27
FUJIFILM Holdings Corp ¥4,992 JPY +257.50
View Industry Companies

Industry Analysis


Industry Average

Valuation ZSAN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 88.5x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZOSANO PHARMA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at